Yes. A 2026 Molecular Therapy study (Jati et al., PMC12776420) demonstrated that exogenous catestatin (CST) supplementation reduced pathological tau species, lowered amyloid plaque burden, and attenuated gliosis in both PS19 tauopathy and 5xFAD amyloid mouse models. The operative mechanism involves CST-mediated suppression of adrenergic–epinephrine–PKA stress signaling, which converges on CDK5 and GSK-3β to reduce tau hyperphosphorylation and amyloidogenic APP processing.
What Is Catestatin and Why Is It Mechanistically Relevant to Neurodegeneration?
Catestatin is a 21-amino acid cationic peptide proteolytically derived from the neuroendocrine prohormone chromogranin A (CgA, residues 352–372). Its canonical role is autocrine inhibition of nicotinic cholinergic-stimulated catecholamine secretion from chromaffin cells. Its relevance to neurodegeneration emerges from the observation that CgA deficiency amplifies adrenergic–epinephrine (EPI) signaling, which drives both tau kinase activation and amyloidogenic APP processing.
Chromogranin A is co-stored and co-released with catecholamines from dense-core secretory granules in adrenal chromaffin cells and sympathetic neurons. Proteolytic cleavage at dibasic sites within the CgA precursor liberates CST, which then acts in a feedback loop to dampen further catecholamine exocytosis via nicotinic receptor blockade. This autocrine brake on sympathoadrenal output is well-characterised in cardiovascular physiology, where CST deficiency correlates with hypertension and elevated plasma catecholamines.
The neurodegeneration connection was established through a prior biorxiv preprint (Jati et al., 2024) showing that CgA-knockout mice exhibit elevated EPI levels, heightened adrenergic receptor (ADR) activity, and accelerated tau pathology. The 2026 Molecular Therapy paper extends this by demonstrating that restoring CST pharmacologically reverses these downstream consequences across two independent transgenic disease models.
Which Mammalian Models Were Used and What Were the Primary Endpoints?
The study employed two established transgenic mouse models: PS19 mice, which express human P301S mutant tau and develop progressive tauopathy with gliosis and motor deficits; and 5xFAD mice, which carry five familial Alzheimer's mutations across APP and PSEN1 and accumulate intraneuronal Aβ42 from approximately 1.5 months of age. Primary endpoints spanned pathological, neuroinflammatory, and functional domains in both lines.
PS19 (B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J) mice develop filamentous tau inclusions in the cortex, hippocampus, and brainstem by 6 months, with accompanying astrogliosis and microgliosis. The 5xFAD model accumulates amyloid plaques rapidly and exhibits both cognitive and motor impairments. Using two mechanistically distinct models — one tau-dominant, one amyloid-dominant — allowed the investigators to assess whether CST's effects were pathway-specific or represented a broader neuroprotective action.
Pathological endpoints included immunohistochemical quantification of phospho-tau epitopes (AT8, AT100), total tau aggregation, amyloid plaque load, and markers of reactive gliosis (GFAP for astrocytes, Iba-1 for microglia). Functional endpoints included Morris water maze and novel object recognition for cognition, and rotarod performance for motor coordination. Mechanistic endpoints focused on EPI levels, PKA substrate phosphorylation, CDK5 activity, and GSK-3β phosphorylation status.
How Does Catestatin Reduce Tau Phosphorylation and Aggregation?
CST reduces tau hyperphosphorylation by suppressing the adrenergic–EPI–PKA axis that activates CDK5 and GSK-3β, the two principal tau kinases implicated in Alzheimer's-type neurofibrillary pathology. In PS19 mice, CST supplementation decreased plasma and brain EPI concentrations, attenuated PKA substrate phosphorylation, and reduced phospho-tau signal at AT8 (Ser202/Thr205) and AT100 (Thr212/Ser214) epitopes relative to vehicle-treated transgenic controls.
The mechanistic chain is as follows: elevated EPI engages β-adrenergic receptors (β-ADR), activating adenylyl cyclase and raising intracellular cAMP. Elevated cAMP activates PKA, which phosphorylates and activates CDK5 activators and also directly phosphorylates tau at multiple serine/threonine residues. PKA-mediated GSK-3β disinhibition further amplifies tau phosphorylation. CST, by reducing EPI release, interrupts this cascade at its upstream node.
Importantly, EPI treatment of primary neurons in vitro markedly increased PKA substrate phosphorylation and tau phosphorylation, and this effect was reversed by CDK5 inhibitors — confirming that CDK5 operates downstream of PKA in this pathway. CST's ability to phenocopy CDK5 inhibition in vivo, without directly targeting the kinase, positions it as an upstream modulator of the entire adrenergic–tau kinase cascade.
What Is the Mechanism Linking Catestatin to Reduced Amyloid Burden?
In 5xFAD mice, CST supplementation lowered amyloid plaque burden through suppression of the adrenergic–PKA axis that drives amyloidogenic APP processing. Elevated EPI-PKA activity promotes BACE1 (β-secretase) expression and enhances γ-secretase-mediated cleavage of APP toward the Aβ42-generating pathway. CST-mediated EPI reduction attenuates this processing bias, shifting APP cleavage toward the non-amyloidogenic α-secretase route.
The convergence of tau and amyloid pathology on a shared upstream adrenergic stress node is the study's central mechanistic claim. Prior work had established that β2-adrenergic receptor activation accelerates both BACE1 transcription (via PKA-CREB) and CDK5-mediated APP phosphorylation, which increases Aβ production. The Jati 2026 data add CST deficiency as a proximal driver of this adrenergic excess, and CST supplementation as a pharmacological means of correcting it.
This mechanism is distinct from the amyloid-clearance strategy pursued by anti-Aβ immunotherapies such as lecanemab and donanemab, which target existing plaques via microglial-mediated phagocytosis. CST instead acts at the production side of the amyloid equation, reducing de novo Aβ generation rather than accelerating its removal. Whether these strategies are additive or redundant in combination remains untested.
How Does Catestatin Suppress Neuroinflammation and Gliosis?
CST attenuated reactive astrogliosis and microglial activation in both PS19 and 5xFAD mice. The anti-inflammatory mechanism involves suppression of NF-κB-driven pro-inflammatory transcription downstream of adrenergic receptor activation. Elevated EPI-ADR signaling activates NF-κB in glial cells; CST-mediated EPI reduction therefore dampens glial NF-κB activity and the cytokine cascade that amplifies tau seeding and plaque-associated inflammation.
Reactive gliosis in tauopathy and amyloid models is not merely a bystander response — activated microglia accelerate tau aggregate seeding and spreading through exosomal release of tau seeds, and astrocyte-derived cytokines (IL-1β, TNF-α, IL-6) further activate tau kinases in neurons. By attenuating glial activation upstream, CST may interrupt a feedforward neuroinflammatory loop that amplifies both tau and amyloid pathology.
The study assessed gliosis immunohistochemically via GFAP and Iba-1 cell counts and morphological scoring. Quantitative cytokine measurements (e.g., ELISA-based IL-1β or TNF-α levels) in brain tissue were not reported, which represents a gap in the mechanistic characterisation of the anti-inflammatory arm.
Downstream NF-κB pathway engagement was inferred from the established adrenergic–NF-κB literature rather than directly measured in this dataset. Direct NF-κB reporter assays or phospho-p65 quantification in CST-treated glial cells would strengthen this mechanistic attribution in future work.
What Cognitive and Motor Functional Outcomes Were Observed?
CST-treated PS19 mice showed improved performance in cognitive assays relative to vehicle-treated transgenic controls, consistent with reduced hippocampal tau burden. In 5xFAD mice, CST treatment improved both cognitive and motor function outcomes. These functional improvements co-occurred with the pathological reductions in tau species, amyloid plaque load, and gliosis, supporting a mechanistic rather than symptomatic interpretation of the behavioral data.
Cognitive improvement in PS19 mice was assessed using paradigms sensitive to hippocampal and cortical circuit integrity. Motor function improvement in 5xFAD mice is notable because the 5xFAD model develops rotarod-detectable motor deficits that are not a primary feature of most Alzheimer's clinical presentations, suggesting CST may have broader neuroprotective effects beyond the canonical AD circuit. The study did not report whether CST-treated mice reached wild-type performance levels or merely showed partial rescue.
Functional outcomes in transgenic mouse models must be interpreted with caution. Behavioral assays in rodents are sensitive to handling stress, circadian variation, and cohort composition. The study design details — including treatment duration, CST dose, route of administration, and blinding procedures — require direct review of the full methods section for complete quality assessment.
What Are the Translational Limitations of This Preclinical Dataset?
The Jati 2026 dataset is mechanistically coherent and cross-validated across two transgenic models, but carries the standard translational limitations of rodent neurodegeneration research: no non-human primate data, no CNS pharmacokinetic characterisation of exogenous CST, no blood-brain barrier permeability data, and no safety or tolerability assessment. The study does not constitute evidence of efficacy in human neurodegeneration.
Transgenic mouse models of tauopathy and amyloidosis recapitulate selected molecular features of human disease but diverge in important ways. PS19 mice express a frontotemporal dementia-associated mutation (P301S), not the sporadic tau pathology that predominates in Alzheimer's disease. The 5xFAD model overexpresses five mutations simultaneously, producing an amyloid burden that exceeds anything observed in human sporadic AD. Translational fidelity is therefore partial at best.
CST's endogenous cardiovascular roles — vasodilation, negative inotropy, catecholamine inhibition — raise the question of whether systemic CST supplementation at neuroprotective doses would produce hemodynamic adverse effects. No cardiovascular safety data were reported in this study. Additionally, the blood-brain barrier penetrance of exogenous CST has not been characterised; it is unclear whether peripherally administered CST acts centrally or whether its effects are mediated through peripheral adrenergic tone reduction that secondarily reduces brain EPI levels.
The study represents a compelling preclinical proof-of-concept for a previously unrecognised neuropeptidergic mechanism linking adrenergic stress to dual tau-amyloid pathology. Advancing this toward translational relevance will require CNS pharmacokinetic studies, non-human primate validation, and identification of a delivery strategy that achieves therapeutic CST concentrations in the brain without cardiovascular liability. What Does 2026 Research Reveal About Semaglutide's Neuroprotective Potential, and Why Did the EVOKE Trials Fail to Confirm It? How Does the Brain-Restricted Peptide BRP Suppress Appetite Without Causing Nausea in 2026 — and How Does It Compare to GLP-1 Drugs? What Does 2026 Research Reveal About the Systems Medicine View of Semaglutide: From Clinical Trials to Molecular Mechanisms?